|
|
|
Insider
Information: |
Isaly Samuel D |
Relationship: |
10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
37 |
|
Direct
Shares |
1,096,936 |
|
Indirect Shares
|
81,677,812 |
|
|
Direct
Value |
$110 |
|
|
Indirect Value
|
$1,073,377,025 |
|
|
Total
Shares |
82,774,748 |
|
|
Total
Value |
$1,073,377,135 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
4
|
0
|
Stock
price went up :
|
4
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
4.0
|
0.0
|
Percentage
Gain/Loss : |
54.4%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
American Cryostem Corporation |
CRYO |
Director, 10% Owner |
2005-07-13 |
1,096,936 |
2005-07-13 |
1,231,936 |
Premium* |
|
Volcano Corp |
VOLC |
Director |
2006-06-20 |
0 |
2006-06-20 |
195,705 |
Premium* |
|
Aryx Therapeutics Inc |
ARYX |
10% Owner |
2007-11-13 |
0 |
2009-05-22 |
1,340,139 |
Premium* |
|
Albireo Pharma Inc |
ALBO |
Director |
2008-02-12 |
0 |
2009-06-10 |
1,485,904 |
Premium* |
|
Athersys Inc (New) |
ATHX |
10% Owner |
2008-05-21 |
0 |
2011-04-26 |
15,250 |
Premium* |
|
Nxstage Medical, Inc. |
NXTM |
Director |
2010-12-09 |
0 |
2010-12-09 |
2,690,476 |
Premium* |
|
Kun Run Biotechnology Inc |
KURU |
10% Owner |
|
0 |
2010-04-30 |
5,228,758 |
Premium* |
|
Anthera Pharmaceuticals Inc |
ANTH |
Director |
2010-09-30 |
0 |
2013-01-30 |
7,462,000 |
Premium* |
|
Amarin Corp Plc |
AMRN |
Director |
|
0 |
2012-09-04 |
5,700 |
Premium* |
|
Pacira Pharmaceuticals, Inc. |
PCRX |
10% Owner |
|
0 |
2012-03-12 |
2,446,000 |
Premium* |
|
Chemocentryx, Inc. |
CCXI |
10% Owner |
2012-02-13 |
0 |
2012-02-13 |
908,509 |
Premium* |
|
Supernus Pharmaceuticals Inc |
SUPN |
Director, 10% Owner |
2012-05-04 |
0 |
2012-05-04 |
297,815 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
|
0 |
2015-02-03 |
1,267,000 |
Premium* |
|
Acceleron Pharma Inc |
XLRN |
Former 10% Owner |
2013-09-24 |
0 |
2013-09-24 |
576,889 |
Premium* |
|
Relypsa Inc |
RLYP |
10% Owner |
2013-11-20 |
0 |
2016-07-25 |
3,356,400 |
Premium* |
|
Roka Bioscience, Inc. |
ROKA |
10% Owner |
|
0 |
2017-10-03 |
0 |
Premium* |
|
Loxo Oncology, Inc. |
LOXO |
Director |
2014-08-06 |
0 |
2017-12-08 |
941,000 |
Premium* |
|
Otonomy, Inc. |
OTIC |
Director |
2014-08-18 |
0 |
2015-11-30 |
1,850,094 |
Premium* |
|
Sientra, Inc. |
SIEN |
10% Owner |
|
0 |
2015-10-12 |
17,100 |
Premium* |
|
Pieris Pharmaceuticals, Inc. |
PIRS |
10% Owner |
|
0 |
2018-01-03 |
49,270 |
Premium* |
|
Glaukos Corp |
GKOS |
Director |
2015-06-30 |
0 |
2017-09-05 |
7,895 |
Premium* |
|
Dimension Therapeutics, Inc. |
DMTX |
Director, 10% Owner |
2015-10-27 |
0 |
2015-10-27 |
5,397,698 |
Premium* |
|
Adaptimmune Therapeutics PLC |
ADAP |
Director |
|
0 |
2017-03-27 |
6,149,377 |
Premium* |
|
Viewray, Inc. |
VRAY |
Director, 10% Owner |
|
0 |
2017-01-18 |
89,225 |
Premium* |
|
Aeglea Biotherapeutics, Inc. |
AGLE |
10% Owner |
|
0 |
2017-02-21 |
1,469,524 |
Premium* |
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2016-05-11 |
0 |
2016-05-11 |
2,662,180 |
Premium* |
|
Corvus Pharmaceuticals, Inc. |
CRVS |
Director, 10% Owner |
2016-05-18 |
0 |
2016-06-24 |
5,379,349 |
Premium* |
|
Selecta Biosciences Inc |
SELB |
Director, 10% Owner |
|
0 |
2016-06-27 |
1,825,415 |
Premium* |
|
Steadymed Ltd. |
STDY |
10% Owner |
|
0 |
2017-04-25 |
2,123,098 |
Premium* |
|
Nabriva Therapeutics AG |
NBRV |
Director, 10% Owner |
|
0 |
2016-12-30 |
391,960 |
Premium* |
|
Aadi Bioscience, Inc |
AADI |
Director, 10% Owner |
2017-03-15 |
0 |
2017-03-15 |
4,416,446 |
Premium* |
|
Cti Biopharma Corporation |
CTIC |
10% Owner |
2017-06-13 |
0 |
2017-06-13 |
5,000,000 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
Director, 10% Owner |
2017-07-24 |
0 |
2017-07-24 |
3,298,516 |
Premium* |
|
Kala Pharmaceuticals, Inc. |
KALA |
10% Owner |
2017-07-25 |
0 |
2018-01-12 |
2,692,715 |
Premium* |
|
Audentes Therapeutics, Inc. |
BOLD |
10% Owner |
2017-09-07 |
0 |
2017-09-29 |
4,129,638 |
Premium* |
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2017-11-21 |
0 |
2017-11-21 |
3,409,865 |
Premium* |
|
X4 Pharmaceuticals Inc |
XFOR |
10% Owner |
2017-11-20 |
0 |
2017-11-20 |
1,868,966 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
251 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 11
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NTLA |
Intellia Therapeutics, In... |
Director |
|
2016-05-11 |
4 |
B |
$18.00 |
$4,500,000 |
I/I |
250,000 |
2,662,180 |
2.1 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-05-18 |
4 |
B |
$11.55 |
$48,510 |
I/I |
4,200 |
5,262,650 |
2.1 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-05-19 |
4 |
B |
$12.11 |
$31,525 |
I/I |
2,600 |
5,265,250 |
2.1 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-05-20 |
4 |
B |
$13.09 |
$61,732 |
I/I |
4,716 |
5,269,966 |
2.25 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2016-05-20 |
4 |
B |
$10.04 |
$24,096 |
I/I |
2,400 |
28,043,404 |
2.1 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2016-05-23 |
4 |
B |
$10.40 |
$12,392,640 |
I/I |
1,191,600 |
29,235,004 |
2.1 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2016-05-24 |
4 |
B |
$10.48 |
$5,432,832 |
I/I |
518,400 |
29,753,404 |
2.1 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-09 |
4 |
B |
$12.95 |
$388,500 |
I/I |
30,000 |
5,299,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-10 |
4 |
B |
$12.98 |
$259,600 |
I/I |
20,000 |
5,319,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-14 |
4 |
B |
$12.71 |
$127,100 |
I/I |
10,000 |
5,329,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-15 |
4 |
B |
$11.94 |
$59,700 |
I/I |
5,000 |
5,334,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-16 |
4 |
B |
$12.04 |
$60,200 |
I/I |
5,000 |
5,339,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-17 |
4 |
B |
$12.48 |
$153,504 |
I/I |
12,300 |
5,352,266 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-21 |
4 |
B |
$12.87 |
$335,688 |
I/I |
26,083 |
5,378,349 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-23 |
4 |
B |
$12.92 |
$1,292 |
I/I |
100 |
5,378,449 |
2.17 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-24 |
4 |
B |
$12.99 |
$11,691 |
I/I |
900 |
5,379,349 |
2.17 |
- |
|
SELB |
Selecta Biosciences Inc |
Director |
|
2016-06-27 |
4 |
B |
$14.00 |
$7,700,000 |
I/I |
550,000 |
1,825,415 |
2.25 |
- |
|
VRAY |
Viewray, Inc. |
Director |
|
2016-08-22 |
4 |
B |
$2.95 |
$3,357,318 |
I/I |
1,138,074 |
86,107 |
2.25 |
- |
|
VRAY |
Viewray, Inc. |
Director |
|
2017-01-18 |
4 |
B |
$3.00 |
$991,731 |
I/I |
330,577 |
89,225 |
2.25 |
- |
|
AGLE |
Aeglea Biotherapeutics, I... |
10% Owner |
|
2017-02-16 |
4 |
B |
$5.04 |
$153,720 |
I/I |
30,500 |
1,390,724 |
1.5 |
- |
|
AGLE |
Aeglea Biotherapeutics, I... |
10% Owner |
|
2017-02-17 |
4 |
B |
$5.19 |
$372,642 |
I/I |
71,800 |
1,462,524 |
1.5 |
- |
|
AGLE |
Aeglea Biotherapeutics, I... |
10% Owner |
|
2017-02-21 |
4 |
B |
$5.36 |
$37,520 |
I/I |
7,000 |
1,469,524 |
1.5 |
- |
|
AADI |
Aadi Bioscience, Inc |
Director |
|
2017-03-15 |
4 |
B |
$5.00 |
$3,814,975 |
I/I |
762,995 |
4,416,446 |
2.25 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2017-03-27 |
4 |
B |
$4.20 |
$4,999,999 |
I/I |
1,190,476 |
6,149,377 |
2.1 |
- |
|
STDY |
Steadymed Ltd. |
10% Owner |
|
2017-04-25 |
4 |
B |
$5.90 |
$6,926,600 |
I/I |
1,174,000 |
2,123,098 |
1.5 |
- |
|
251 Records found
|
|
Page 3 of 11 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|